Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review

被引：0
|
作者：
Peixin Huang
Yingting Zhou
Yi Chen
机构：
[1] Zhongshan Hospital,Department of Hepatic Oncology
[2] Liver Institute,undefined
[3] Zhongshan Hospital,undefined
来源：
Journal of Gastrointestinal Cancer | 2022年 / 53卷
关键词：
Immune checkpoint inhibitors; Camrelizumab; Targeted therapy; Recurrent intrahepatic cholangiocarcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：817 / 824
页数：7
相关论文
共 50 条
  • [1] Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review
    Huang, Peixin
    Zhou, Yingting
    Chen, Yi
    JOURNAL OF GASTROINTESTINAL CANCER, 2022, 53 (03) : 817 - 824
  • [2] Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review
    Zhang, Haitao
    Han, Cuiping
    Zheng, Xiaohuan
    Zhao, Wenhua
    Liu, Yuanshui
    Ye, Xin
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (04) : 1055 - 1060
  • [3] Precision therapy for intrahepatic cholangiocarcinoma: A case report on adjuvant treatment in a recurrent patient after surgery and literature review
    Ying, Bao
    Tang, Tao
    Zhang, Li-Xing
    Xiong, Jian-Wei
    Zhao, Kai-Feng
    Li, Jia-Wei
    Wu, Guo
    ONCOLOGY LETTERS, 2024, 27 (02)
  • [4] Complete response of recurrent perihilar cholangiocarcinoma following sintilimab combined with lenvatinib plus S-1: a case report and review of literature
    Liu, Qin-qin
    Yu, Xian-huan
    Tang, Qi-bin
    Chen, Dong
    Zhang, Rui
    Liu, Chao
    Shi, Xiang-de
    ANTI-CANCER DRUGS, 2024, 35 (01) : 81 - 85
  • [5] Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
    Lefler, Daniel S.
    Tierno, Marni Brisson
    Bashir, Babar
    CANCER BIOLOGY & THERAPY, 2022, 23 (01) : 112 - 116
  • [6] A case of camrelizumab-induced anaphylaxis and successful rechallenge: a case report and literature review
    Song, Ping
    Jin, Yuqi
    Dai, Lifang
    Fang, Lijun
    Tan, Yinuo
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [7] Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: A case report and literature review
    Tan, Youwen
    Ye, Yun
    Chen, Li
    OPEN MEDICINE, 2021, 16 (01): : 553 - 557
  • [8] Targeted therapy with anlotinib for patient with recurrent glioblastoma A case report and literature review
    Lv, Yajuan
    Zhang, Jiandong
    Liu, Fengjun
    Song, Meijuan
    Hou, Yong
    Liang, Ning
    MEDICINE, 2019, 98 (22)
  • [9] Camrelizumab for the treatment of advanced cervical adenocarcinoma: case report and literature review
    Zhang, Lei
    Jiang, Yuqi
    Xue, Chaofan
    Chen, Huiyong
    Zhang, Yongchun
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (04)
  • [10] Anti-PD-1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review
    Kong, Fengwei
    Wang, Weimin
    Gong, Longbo
    Wu, Wenbin
    Liu, Yuanyuan
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (06) : 1489 - 1496
12345